abstract |
The present invention concerns a conjugate comprising (i) a cell binding agent which binds to the human mucin-1 (MUC1) glycoprotein, linked to (ii) at least one cytotoxic agent, for use in a method for treating cancer, wherein the method comprises at least two cycles, wherein, for each cycle, the conjugate is administered at a dose corresponding to that of an administration schedule of at least 60 mg/m 2 every week of the cycle, and wherein the conjugate is administered at least two times during each cycle. |